Litigation Details for Purdue Pharma L.P. v. Amneal Pharmaceuticals, LLC (D. Del. 2017)
✉ Email this page to a colleague
Purdue Pharma L.P. v. Amneal Pharmaceuticals, LLC (D. Del. 2017)
Docket | ⤷ Sign Up | Date Filed | 2017-03-01 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:0145 | Assigned To | Richard Gibson Andrews |
Jury Demand | None | Referred To | |
Patents | 8,808,741; 8,894,987; 8,894,988; 9,073,933; 9,492,392; 9,492,393; 9,522,919 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Purdue Pharma L.P. v. Amneal Pharmaceuticals, LLC
Details for Purdue Pharma L.P. v. Amneal Pharmaceuticals, LLC (D. Del. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2018-05-21 | 97 | Opinion - Memorandum Opinion | #39;393 patents are related to and have the same specification as U.S. Patent Nos. 8,808,741 ("the…U.S. Patent Nos. 9,492,392 ("the '392 patent"), 9,492,393 ("the '393 patent"…infringe a number of Plaintiffs' patents. (D.I. 1). The patents- in-suit relate to OxyContin®, an …;the '741 patent"), 8,894,987 ("the '987 patent), and 8,894,988 ("the '988…988 patent"). (D.I. 48 at 9). The '919 patent is related to and has the same specification as | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |